ObsEva
Plan-les-ouates
About ObsEva
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $228.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2019)
- Ticker: nasdaq:OBSV
- Website: obseva.com
- Phone: +41 (0)22 552 3840
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics, Women's
Social Profiles
Canonical: https://fsome.com/organization/obseva-138427 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.